NN 4201Alternative Names: NNC 421001
Latest Information Update: 18 Feb 2002
At a glance
- Originator Novo Nordisk
- Mechanism of Action Glycogen phosphorylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 18 Feb 2002 Discontinued-I for Type-2 diabetes mellitus in Denmark (Unknown route)
- 02 May 2000 Phase-I clinical trials for Type-2 diabetes mellitus in Denmark (Unknown route)
- 16 Apr 1999 New profile